Prostate Cancer Treatment. The Case for Radical Prostatectomy

Overview

Journal Ann R Coll Surg Engl

Specialty General Surgery

Date 2006 Sep 28

PMID 17002843

Citations 1

Authors

Miles A Goldstraw

Affiliations

Soon will be listed here.

Citing Articles

Antrocin Sensitizes Prostate Cancer Cells to Radiotherapy through Inhibiting PI3K/AKT and MAPK Signaling Pathways.

Chen Y, Tzeng D, Huang Y, Lin C, Lo U, Wu C Cancers (Basel). 2019; 11(1).

PMID: 30602706 PMC: 6356781. DOI: 10.3390/cancers11010034.

References

Martinez A, Gonzalez J, Chung A, Kestin L, Balasubramaniam M, Diokno A . A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution. Cancer. 2000; 88(2):425-32. DOI: 10.1002/(sici)1097-0142(20000115)88:2<425::aid-cncr25>3.0.co;2-z. View

RAGDE H, Korb L, Elgamal A, Grado G, Nadir B . Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer. 2000; 89(1):135-41. View

Potters L, Torre T, Fearn P, Leibel S, Kattan M . Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2001; 50(5):1235-42. DOI: 10.1016/s0360-3016(01)01578-4. View

RAGDE H, Grado G, Nadir B . Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone. Arch Esp Urol. 2001; 54(7):739-47. View

DAmico A, Whittington R, Malkowicz S, Cote K, Loffredo M, Schultz D . Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002; 95(2):281-6. DOI: 10.1002/cncr.10657. View

Augustin H, Pummer K, Daghofer F, Habermann H, Primus G, Hubmer G . Patient self-reporting questionnaire on urological morbidity and bother after radical retropubic prostatectomy. Eur Urol. 2002; 42(2):112-17. DOI: 10.1016/s0302-2838(02)00259-2. View

Steineck G, Helgesen F, Adolfsson J, Dickman P, Johansson J, Norlen B . Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002; 347(11):790-6. DOI: 10.1056/NEJMoa021483. View

Henderson A, Cahill D, Laing R, Langley S . (125)Iodine prostate brachytherapy: outcome from the first 100 consecutive patients and selection strategies incorporating urodynamics. BJU Int. 2002; 90(6):567-72. DOI: 10.1046/j.1464-410x.2002.02983.x. View

Vicini F, Martinez A, Hanks G, Hanlon A, Miles B, Kernan K . An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer. 2002; 95(10):2126-35. DOI: 10.1002/cncr.10919. View

10.

Robinson J, Moritz S, Fung T . Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys. 2002; 54(4):1063-8. DOI: 10.1016/s0360-3016(02)03030-4. View

11.

Jani A, Hellman S . Early prostate cancer: clinical decision-making. Lancet. 2003; 361(9362):1045-53. DOI: 10.1016/S0140-6736(03)12833-4. View

12.

Sylvester J, Blasko J, Grimm P, Meier R, Malmgren J . Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys. 2003; 57(4):944-52. DOI: 10.1016/s0360-3016(03)00739-9. View

13.

Potters L, Huang D, Calugaru E, Fearn P, Lee L, Kattan M . Importance of implant dosimetry for patients undergoing prostate brachytherapy. Urology. 2003; 62(6):1073-7. DOI: 10.1016/j.urology.2003.07.004. View

14.

Kupelian P, Potters L, Khuntia D, Ciezki J, Reddy C, Reuther A . Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2003; 58(1):25-33. DOI: 10.1016/s0360-3016(03)00784-3. View

15.

Potosky A, Davis W, Hoffman R, Stanford J, Stephenson R, Penson D . Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004; 96(18):1358-67. DOI: 10.1093/jnci/djh259. View

16.

Walsh P, DONKER P . Impotence following radical prostatectomy: insight into etiology and prevention. J Urol. 1982; 128(3):492-7. DOI: 10.1016/s0022-5347(17)53012-8. View

17.

Paulson D, Lin G, Hinshaw W, Stephani S . Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol. 1982; 128(3):502-4. DOI: 10.1016/s0022-5347(17)53016-5. View

18.

Lu-Yao G, Yao S . Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet. 1997; 349(9056):906-10. DOI: 10.1016/S0140-6736(96)09380-4. View

19.

Wieder J, Soloway M . Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol. 1998; 160(2):299-315. View

20.

Albertsen P, Hanley J, GLEASON D, Barry M . Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998; 280(11):975-80. DOI: 10.1001/jama.280.11.975. View